PubRank

Anna C Pavlick

Author PubWeight™ 84.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
2 Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 7.51
3 Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006 7.33
4 Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012 6.21
5 KIT as a therapeutic target in metastatic melanoma. JAMA 2011 3.49
6 Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010 2.65
7 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013 2.51
8 Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2012 2.45
9 Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 2012 2.40
10 Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009 2.32
11 A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2010 2.09
12 Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008 2.00
13 Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res 2010 1.59
14 Mucosal melanomas: a case-based review of the literature. Oncologist 2010 1.20
15 Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 2007 1.18
16 A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 2010 1.17
17 Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008 1.14
18 Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2012 1.12
19 Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013 1.08
20 Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 2012 1.06
21 Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer 2009 1.03
22 Histology-specific microRNA alterations in melanoma. J Invest Dermatol 2012 0.99
23 Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol 2011 0.99
24 Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 2009 0.97
25 Novel therapeutics for melanoma. Expert Rev Anticancer Ther 2009 0.96
26 Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol 2012 0.96
27 Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013 0.96
28 Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol 2005 0.95
29 Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer 2009 0.93
30 Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res 2010 0.92
31 A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Invest New Drugs 2010 0.91
32 Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007 0.91
33 Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res 2008 0.89
34 Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas. Am J Clin Oncol 2002 0.88
35 Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol 2012 0.87
36 Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients. J Transl Med 2008 0.83
37 Update on vaccines for high-risk melanoma. Curr Treat Options Oncol 2014 0.83
38 Targeted therapies for metastatic melanoma. Dermatol Clin 2012 0.82
39 Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy 2009 0.81
40 Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro Oncol 2012 0.81
41 Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drugs 2011 0.81
42 Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis. Am J Surg Pathol 2013 0.79
43 Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Oncology 2012 0.78
44 Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. J Community Health 2011 0.78
45 A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One 2010 0.76
46 A high proliferative index of recurrent melanoma is associated with worse survival. Oncology 2011 0.75
47 Impact of age on the management of primary melanoma patients. Oncology 2013 0.75
48 Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology 2017 0.75
49 Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother 2017 0.75
50 Metastatic Cutaneous Squamous Cell Carcinoma: The Importance of T2 Stratification and Hematologic Malignancy in Prognostication. Dermatol Surg 2016 0.75
51 Ewing sarcoma in an octogenarian: a case report. J Bone Joint Surg Am 2002 0.75
52 Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology 2017 0.75